Video

Dr. Mehta on the Role of Biomarkers in Gastric Cancer

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Rutika J. Mehta, MD, MPH, a medical oncologist specializing in gastrointestinal cancer at Moffitt Cancer Center, discusses the role of biomarkers in gastric cancer.

Biomarkers such as microsatellite instability, mismatch repair ​deficiency, HER2 status, PD-L1 ​status, and tumor mutational burden are of interest in the gastric cancer space, says Mehta.

​Moreover, according to Mehta, all patients ​with metastatic disease should be ​molecularly profiled. 

​Additionally, if tissue is available, ordering next​-generation sequencing may be beneficial ​in terms of treatment selection and identifying available clinical trials, Mehta concludes. 

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School